X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SCI-210 a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide), which is being evaluated for the treatment of Autism Spectrum Disorder in children between 5 and 18 years.
Lead Product(s): Cannabidiol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2024
Details:
SCI- 210 consisits of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA (palmitoylethanolamide). It is being developed for the treatment of Autism Spectrum Disorder.
Lead Product(s): Palmitoylethanolamide,Cannabidiol
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
The combination treatment includes palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of the Company’s proprietary CannAmide, and MEAI, Clearmind’s novel proprietary psychedelic treatment for various addictions, obesity, and depression.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: SCI-210
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
CMND-100 (5-methoxy-2-aminoindane) is a MEAI-based psychedelic-derived drug candidate which is being investigated for the treatment of Alcohol Use Disorder. MEAI breaks the vicious binge-drinking cycle by innervating 5-HT1A neural pathways.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Details:
The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia to occur in several rapid, non-rhythmic, abnormal movements disorders including Tourette Syndrome and Parkinson's disease.
Lead Product(s): 3-Methylmethcathinone,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hannover Medical School
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for Tourette Syndrome to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
The collaboration aims to evaluate Clearmind's and SciSparc's combination treatment of MEAI (5-methoxy-2-aminoindane), a novel proprietary psychedelic treatment, and PEA (phenethylamine), the active ingredient of CannAmide, for obesity and metabolic syndrome.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Nutrition and Weight Loss Product Name: CMND-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hebrew University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for alzheimer's disease and agitation to stimulate cannabinoid receptors across the CNS and inhibit the degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
SCI-110 contains dronabinol with the endocannabinoid palmitoylethanolamide. It is developed for alzheimer's disease and agitation to stimulate cannabinoid receptors across the CNS and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
The collaboration aims to strengthens IP portfolio with patent application in the U.S. For treatment of depression. The latest patent application refers to the protection of the unique combination of MEAI and SciSparc's Palmitoylethanolamide (PEA).
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 21, 2023
Details:
The objective of this clinical trial is to evaluate the efficacy, safety and tolerability of SciSparc's proprietary drug candidate SCI-110 (dronabinol) in adult patients (between 18 and 65 years of age) using daily oral treatment.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol, and CannAmide™, the Company's proprietary formulation of Palmitoylethanolamide (PEA).
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
SCI-110, contains dronabinol with the endocannabinoid palmitoylethanolamide. It is designed to stimulate cannabinoid receptors across the CNS and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
Under the collaboration, three provisional patent applications were filed by Clearmind. The patent applications refer to novel proprietary combinations of LSD, psilocybin, and DMT and SciSparc’s Palmitoylethanolamide, the active ingredient of its proprietary CannAmide™.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2023
Details:
FSD201 (palmitoylethanolamide) with enhanced anti-inflammatory properties, it is a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy making it suitable to treat a range of inflammatory conditions
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Musculoskeletal Product Name: FSD201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol, and CannAmide™, the Company's proprietary formulation of Palmitoylethanolamide (PEA).
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Soroka Medical Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 09, 2023
Details:
The non-clinical trial objective was to study the potential therapeutic effects of SCI-210 on SE and on neuro-biochemical markers for neurological cognitive sequelae. A pilocarpine SE-induced mice model to study SCI-210’s effects on seizure severity and mortality was used.
Lead Product(s): Cannabidiol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
SCI-110 is a unique and proprietary combination of Dronabinol, an FDA-Approved, synthetic version of delta-9-tetrahydrocannabinol (Δ⁹-THC), and CannAmide™, the Company’s proprietary formulation of Palmitoylethanolamide.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
The patent application is the third collaboration, each referring to the combination of SciSparc's Palmitoylethanolamide (PEA), the active ingredient of CannAmide™ and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions.
Lead Product(s): Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 22, 2022
Details:
FSD201 is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA). FSD Pharma’s successfully completed Phase 1 clinical trial showed FSD201 to be safe and well tolerated.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Musculoskeletal Product Name: FSD201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
The primary safety objective of the trial will be to assess absolute and relative frequencies of serious adverse events for the entire population and separately for the SCI-110 (dronabinol) and placebo groups.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yale University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 01, 2022
Details:
FSD-201 (palmitoylethanolamide) stabilizes mast cells and down-regulates pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of endocannabinoid system of human body.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Immunology Product Name: FSD-201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
SCI -110 is a combination of dronabinol, the active ingredient in an FDA-approved synthetic analog of tetrahydrocannabinol, in patients suffering from Tourette Syndrome.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hannover Medical School
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 08, 2022
Details:
SCI-110 (Dronabinol) in adult patients (between 18 and 65 years of age) using oral treatment daily. The patients will be randomized in a 1:1 ratio to receive either SCI-110 or a SCI-110 matched placebo.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Based on statistically significant reductions in the reward effect as compared to cocaine, it was determined that MEAI, (5-methoxy-2-aminoindane, a novel psychoactive substance) is not rewarding.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
The patent application refers to the proprietary combination of Clearmind's MEAI (5-methoxy-2-aminoindan), a novel proprietary psychedelic treatment for addiction, with SciSparc's CannAmide™.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 02, 2022
Details:
FSD Pharma holds exclusive worldwide (excluding Italy and Spain) licensing rights to FSD-201 for all conditions in all regulatory categories. FSD-201 (Palmitoylethanolamide) is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA).
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Immunology Product Name: FSD-201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
The primary safety objective of the study will be to assess absolute and relative frequencies of serious adverse events for the entire population and separately for the SCI-110 (dronabinol) and placebo groups.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yale University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
The patent application followed a pre-clinical study that showed a significant dose-dependent effect for MEAI treatment in reducing alcohol consumption of treated animals, with additional significant effect for the CannAmide treatment at lower, sub-effective MEAI dose.
Lead Product(s): 5-Methoxy-2-Aminoindane,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: MEAI
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 10, 2022
Details:
Results showed a significant dose dependent effect for the MEAI treatment in reducing alcohol consumption of the treated animals, with additional significant effect for the CannAmide™ treatment at the lower sub-effective MEAI dose.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: CannAmide
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clearmind Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
SciSparc is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yale University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2021
Details:
SciSparc has entered an agreement with The Sheba Fund for Health Services and Research, to perform a pre-clinical study for the evaluation of the Company's SCI-210 drug development program.
Lead Product(s): Cannabidiol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-210
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Sheba Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
The Israeli Medical Center for Alzheimer's will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and agitation.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Neurology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 23, 2021
Details:
SCI-110 is an innovative proprietary combination drug candidate, formulated to treat the symptoms related to diseases of the central nervous system.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: SCI-110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SciSparc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 10, 2021
Details:
FDA has authorized randomized, controlled, double-blind study on 352 patients. The Company is expected to conduct this trial in 25-30 Medical Centers and Hospitals in North America.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
The U.S FDA has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The FSD201 COVID-19 Trial will be a multicenter study that assesses the efficacy and safety of FSD201 dosed at 600mg or 1200mg twice-daily, together with standard of care compared to SOC alone in hospitalized patients with COVID-19 disease.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
Details:
FSD Pharma announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Infections and Infectious Diseases Product Name: FSD201
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
The trial will be a randomized, controlled, double-blind, U.S. multicenter study to assess the efficacy and safety of FSD-201 dosed 600mg/1200mg twice-daily plus standard of care versus SOC alone in symptomatic patients with clinical presentation compatible with COVID-19.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
As part of the joint venture, Therapix transferred to Evero its THX-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement.
Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evero
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 19, 2020
Details:
Approval to initiate a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of ultra-micronized-PEA in normal healthy volunteers.
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
